Breast cancer, Secondary cancers
Results
Phase 2
This trial compared giredestrant with standard treatment for breast cancer that had either come back after treatment or spread.
It was for people whose breast cancer cells:
had receptors for the hormone oestrogen (oestrogen receptor positive or ER positive cancer)
did not have receptors for the protein HER 2 (HER2 negative cancer)
The trial was open for people to join between 2020 and 2021. The team published the results in 2024.
You pronounce giredestrant as jeer-a-das-trant.
Recruitment start: 25 February 2021
Recruitment end: 13 October 2021
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Sarah Khan
Roche
Last reviewed: 04 Feb 2025
CRUK internal database number: 17341
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
